Today, PODD: Partnership Opportunities in Drug Delivery – the leading event reporting on key developments in drug delivery technologies – announced the agenda and featured sessions for its 15th annual conference, which will take place on October 27-28 at the Westin Copley Place in Boston, MA.
The PODD Conference fosters collaborations between pharmaceutical, biotech and drug delivery companies to develop more effective therapies for patients.
The 2025 featured sessions include:
Partnering to Advance Drug Delivery Innovation led by Dr Ester Caffarel-Salvador, Director, Strategic Innovation, Rare Diseases, Chiesi USA with panelists Dr Sean Bedingfield, R&D Advisor – Genetic Medicine, Eli Lilly and Company, Dr Annette Bak, Head of Advanced Drug Delivery, AstraZeneca, Dr Jaymin Shah, Head of Global Biopharmaceutics and Senior Research Fellow, Pfizer, and Dr Rashmi Thakur, Director, Portfolio Strategy & Integration, BMS. The panelists will address key strategic considerations in evaluating external drug delivery technologies and partnership pathways and approaches for companies at different stages of technology development.
Novartis’s Global Head of Innovation, Dr Mateja Kramer, and AbbVie’s Senior Director, Landscaping & Platform Definition, Dr Nicholas Schill, will present on their companies’ partnering philosophy, current needs and scouting interests, as related to drug delivery and enabling technologies as part of the Pharma Company Spotlights.
Mark Simon of Sun Pharmaceutical Industries, Lambert van der Walde of UnitedHealth Group, Dr Michael Sherman of RA Capital Management, and Dr Gail Ryan, formerly of Point32Health, will lead the Payer Perspectives on Drug Delivery panel to discuss pharmacoeconomics of drug delivery enabled drug product, demonstrating value to the patient and system, pressures on drug pricing and leveraging health economics and trends in coverage and pricing for the incretin and nucleic acid drugs.
The 2025 Drug Delivery Technology Presentations cover the following:
- Injectable Formulations & Technologies
- Novel Devices: Self-Injectables, Wearables & Connected Devices
- Oral, Nasal, Pulmonary & Other Non-Injectable Technologies
- Cell & Gene Delivery
- Excipient Innovation
- Novel Device Technologies
- Novel Injectable & Non-Injectable Technologies
- Cell, Gene & Novel Biologics Delivery
- Self-Injection Devices, Syringes, Primary Container & Packaging Solutions
Additional topic areas include:
- Delivering Genetic Medicines with Novel Vehicles
- Physical and Formulation Approaches for Brain Delivery
- Platform Approaches to Streamline Combination Product Development
- Novel Approaches to Achieve Tissue-Specific Targeting for Nucleic Acid Therapeutics
- Advances in ADCs, Drug Conjugation and Bioconjugation
- Achieving Effective Manufacturing Scaleup for Clinical and Commercial Success
- Ensuring Sustainability Throughout Drug and Device Development
- And more
“We are proud to connect industry leaders and innovators who advance the design and development of drug delivery systems and devices to improve patient lives,” said Andrew Goldstein, Senior Conference Producer for the PODD Conference.
Pharmaceutical companies presenting include: AbbVie, Amgen, Astellas Pharma, AstraZeneca, Asklepios BioPharmaceutical, Astria Therapeutics, Azura Ophthalmics, Beam Therapeutics, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi USA, Eli Lilly & Company, Genentech, Gilead Sciences, GSK, Merck, Moderna, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi, Sun Pharma, Takeda Pharmaceuticals, Teva Pharmaceuticals and UCB.
To learn more about the event, visit PODDConference.com.
